Organon director granted 17,857 phantom stock units
Organon & Co. director Shalini Sharp reported a routine compensation grant of phantom stock units.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Organon & Co. director Shalini Sharp reported a routine compensation grant of phantom stock units. She received 17,857.143 phantom stock units on the transaction date, each economically equivalent to one share of Organon common stock on a 1-for-1 basis at a reference value of $13.44 per unit.
Following this grant, her holdings of phantom stock units increased to 81,495.885. These units were granted under the Organon Non-Employee Director Savings Plan and are payable in cash after her termination of service as a director, in accordance with the plan’s terms. Holdings also reflect phantom stock acquired through dividend reinvestment on specified past dates.
Insights
Routine cash-settled director compensation grant with no direct share trading.
The filing shows Shalini Sharp, a director of Organon & Co., receiving 17,857.143 phantom stock units as a grant under the Non-Employee Director Savings Plan. This is a standard form of non-cash compensation tied to the company’s share value.
Each phantom unit mirrors one common share economically but is payable in cash after board service ends, so there is no immediate issuance of common stock or market trade. After the grant, her phantom stock balance is 81,495.885 units, including prior dividend reinvestments. This is a typical governance and compensation disclosure rather than a directional trading signal.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Phantom Stock | 17,857.143 | $13.44 | $240K |
Footnotes (3)
- F1. Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1.
- F2. Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.
- F3. Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026.
Key Figures
Key Terms
Phantom stock units financial
Organon Non-Employee Director Savings Plan financial
Dividend reinvestment transactions financial
Grant, award, or other acquisition financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did OGN director Shalini Sharp report on this Form 4?
How many phantom stock units does Shalini Sharp hold in Organon (OGN) after this grant?
What is phantom stock in the context of Organon (OGN) director compensation?
Does this Organon (OGN) Form 4 show any open-market stock purchases or sales?
How and when are Organon (OGN) phantom stock units paid to directors?
AI-generated analysis. How Rhea-AI works. Not financial advice.